Current glucose management for patients with esophageal cancer predominantly focuses on insulin pharmacotherapy [5], but medication‐based approaches carry hypoglycemic risks and have limitations in regulating metabolic disorders [9]. The gene discussed is INS; the disease is esophageal cancer.